Essentials · Evidence reviewed
Can teenagers use prescription weight-loss medicine?
Weight-loss medications are not exclusively studied in adults, but pediatric use requires different evidence, eligibility criteria and clinical oversight. The FDA has approved certain prescription treatments for adolescents under particular conditions. That does not make every adult weight-loss drug suitable for a teenager.
Which age groups have approvals?
The FDA approved Saxenda for eligible adolescents ages 12 and older in 2020. Later pediatric approvals include some other weight-management medications, such as Qsymia, with specific age and obesity criteria. Approvals and formulations vary; always check the current individual product label.
Why is pediatric BMI different?
Children and adolescents are still growing. Clinicians generally use BMI-for-age percentiles rather than applying adult BMI cutoffs without adjustment. Puberty, development, existing health conditions and treatment history matter.
What did the Saxenda study examine?
The FDA described a 56-week randomized, placebo-controlled trial among 251 adolescents ages 12 through 17. Participants received lifestyle counseling. Pediatric efficacy is often evaluated using age-adjusted BMI measures, not just total pounds lost.
Who makes the treatment decision?
A pediatric clinician with appropriate expertise should assess eligibility, risks, possible adverse effects and follow-up needs. Medication is one part of care; family support and nutrition deserve attention without stigmatizing the teenager.
What about newer adult drugs?
Do not assume a drug is approved for adolescents just because it is widely prescribed in adults. Approval can differ between injections, tablets and strengths, and changes over time.
The bottom line
Some prescription treatments are FDA-approved for certain adolescents, but there is no blanket approval for all obesity medicines in people under 18.
Written and published by MyDosePro as an educational explanation of publicly available evidence. The linked primary source is dated 2020-12-04. We identify trial registrations separately from published results and do not provide individual prescribing advice.
Primary sourceFDA pediatric Saxenda approval ↗
Additional evidenceThis guide explains published evidence; source dates may be older than the review date. Our interpretation is educational and does not replace medical or insurance advice.